Bavarian Nordic injects debt for GSK vaccines

Injection_Fotolia_230x150
By Mike Turner
21 Oct 2019

Denmark’s Bavarian Nordic will buy two commercial vaccines from GlaxoSmithKline for €796m, in a debt funded acquisition that will be refinanced next year in the equity market.

Biological sciences company Bavarian Nordic has agreed to buy rabies vaccine Rabipur and tick-borne encephalitis preventative Encepur from the UK drugs company. 

The acquisition includes a €301m upfront payment on the deal closing, which is expected to happen before the end of this year. Bavarian Nordic will then pay ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.